Краткий ответ
Trial results are reported in a language designed for precision, then translated into headlines designed for attention. A few habits protect you: check how many people were treated, check how long they were followed, check whether there was a comparison group, and check whether the thing measured is the thing you care about.
Interpretation depends on phase, sample size, follow-up duration, control design and endpoint choice. Early-phase studies are typically single-arm and small, so response rates carry wide confidence intervals and lack a comparator. A surrogate endpoint, such as a protein level used as a biomarker, may or may not predict clinical benefit. In one-time therapies, durability is a primary question that only time can answer.
Questions worth asking
- How many people? Three participants improving is a signal to investigate, not a result to rely on.
- Compared with what? Without a control group, you cannot separate the treatment from the natural course of the illness.
- Measured how? A change in a blood marker is not the same as living longer or feeling better.
- For how long? In a permanent therapy, six months of data says almost nothing about twenty years.
- Who reported it? A peer-reviewed paper, a conference abstract and a company press release are three different levels of scrutiny.
- What did the harms look like? Benefit without a serious account of adverse events is an incomplete result.
Sources
- ClinicalTrials.gov
Learn about clinical studies ↗
Проверьте своё понимание: Advanced
No score is stored and nothing is sent anywhere. This is just for you.
1. A press release reports a 90% reduction in a blood protein. What should you check first?
Why: A large effect in a handful of people over a few months is a promising signal, not proof of benefit. Size, duration and comparator decide what it means.
2. Why is multiplex editing harder than single editing?
Why: Multiple simultaneous breaks raise the risk of translocations, pieces of chromosome joining the wrong partner. Risk does not scale linearly with the number of edits.
3. What mainly drives the price of an approved cell therapy?
Why: A bespoke product made per patient, plus a hospital stay, spread across a small population, is the bulk of it, not the cost of the editing molecules.
4. CRISPR diagnostics use the technology to do what?
Why: Cas12 and Cas13 chop nearby reporter molecules once they find their target, producing a readable signal. Nothing in the patient is edited.